Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
第一作者机构:[1]Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Zhang Xiaoshuai,Yu Lu,Zhou Li,et al.Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis[J].BLOOD.2024,144:4529-4530.doi:10.1182/blood-2024-203533.
APA:
Zhang, Xiaoshuai,Yu, Lu,Zhou, Li,Zhang, Yanli,Zhu, Huanling...&Jiang, Qian.(2024).Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis.BLOOD,144,
MLA:
Zhang, Xiaoshuai,et al."Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis".BLOOD 144.(2024):4529-4530